Leprosy primary prevention: Difference between revisions
(Created page with "__NOTOC__ {{Leprosy}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. ==References== {{reflist|2}} ...") |
m (Changes made per Mahshid's request) |
||
| (22 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Leprosy}} | {{Leprosy}} | ||
{{CMG}}; {{AE}} {{JS}} | |||
==Overview== | |||
[[Primary prevention]] of leprosy includes [[immunoprophylaxis]], [[chemoprophylaxis]] and education of the populations to prevent [[infection]] by the ''[[Mycobacterium leprae]]''. | |||
==Primary prevention== | |||
There are still [[endemic]] regions in the world affected by leprosy. Due to international travels, these may be a source of the [[bacteria]] for the rest world. | |||
There is still no adequate tool for the early detection of leprosy. [[Immunoprophylaxis]] studies in different population groups with the [[BCG vaccine]], alone or in combination with killed [[Mycobacterium leprae]] or atypical [[Mycobacteria]], have shown an [[efficacy]] of 28 to 60%. A good coverage of [[BCG vaccine]] is still a major contribution to reduce the impact of leprosy in populations.<ref name=WHO>{{cite web | title = Enhanced Global Strategy for Further Reducing the Disease Burden due to Leprosy | url = http://www.searo.who.int/entity/global_leprosy_programme/documents/enhanced_global_strategy_2011_2015_operational_guidelines.pdf }}</ref> | |||
[[Chemoprophylaxis]] of [[chronic]] [[infectious diseases]] has also shown benefits, particularly in populations with higher [[Risk factor|risk]] of [[infection]] with leprosy. However, it is still early to define [[chemoprophylaxis]] as a [[public health]] measure, as more [[Clinical trial|trials]] are needed to demonstrate [[safety]], [[efficacy]] and [[cost-effectiveness]] of these therapies.<ref name=WHO>{{cite web | title = Enhanced Global Strategy for Further Reducing the Disease Burden due to Leprosy | url = http://www.searo.who.int/entity/global_leprosy_programme/documents/enhanced_global_strategy_2011_2015_operational_guidelines.pdf }}</ref> | |||
Other important element of [[primary prevention]] is the education of populations. Immediate contacts of leprosy patients have higher [[Risk factor|risk]] of being [[infected]], therefore they should be aware of the condition, its [[transmission]] and what to do to minimize this [[Risk factor|risk]].<ref name=WHO>{{cite web | title = Enhanced Global Strategy for Further Reducing the Disease Burden due to Leprosy | url = http://www.searo.who.int/entity/global_leprosy_programme/documents/enhanced_global_strategy_2011_2015_operational_guidelines.pdf }}</ref> | |||
==References== | ==References== | ||
| Line 12: | Line 22: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Dermatology]] | [[Category:Dermatology]] | ||
[[Category:Tropical disease]] | [[Category:Tropical disease]] | ||
[[Category:Leprosy]] | [[Category:Leprosy]] | ||
| Line 18: | Line 28: | ||
[[Category:Bacterial diseases]] | [[Category:Bacterial diseases]] | ||
[[Category:Neglected diseases]] | [[Category:Neglected diseases]] | ||
Latest revision as of 18:10, 18 September 2017
|
Leprosy Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Leprosy primary prevention On the Web |
|
American Roentgen Ray Society Images of Leprosy primary prevention |
|
Risk calculators and risk factors for Leprosy primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]
Overview
Primary prevention of leprosy includes immunoprophylaxis, chemoprophylaxis and education of the populations to prevent infection by the Mycobacterium leprae.
Primary prevention
There are still endemic regions in the world affected by leprosy. Due to international travels, these may be a source of the bacteria for the rest world. There is still no adequate tool for the early detection of leprosy. Immunoprophylaxis studies in different population groups with the BCG vaccine, alone or in combination with killed Mycobacterium leprae or atypical Mycobacteria, have shown an efficacy of 28 to 60%. A good coverage of BCG vaccine is still a major contribution to reduce the impact of leprosy in populations.[1]
Chemoprophylaxis of chronic infectious diseases has also shown benefits, particularly in populations with higher risk of infection with leprosy. However, it is still early to define chemoprophylaxis as a public health measure, as more trials are needed to demonstrate safety, efficacy and cost-effectiveness of these therapies.[1]
Other important element of primary prevention is the education of populations. Immediate contacts of leprosy patients have higher risk of being infected, therefore they should be aware of the condition, its transmission and what to do to minimize this risk.[1]